Reimbursed Care Access in Bolivia

Currently classified as a strictly controlled substance under Bolivia's national drug‑control statute (Ley del Régimen de la Coca y Sustancias Controladas — Ley 1008), which lists psilocybin/psilocin among Schedule I psychotropic substances; there is no authorized medical use or reimbursement outside approved clinical research. # Standard legal consequences for unauthorized possession/trafficking apply (rehabilitation measures for small amounts; heavy penalties for trafficking).

Currently classified as a strictly controlled substance under national drug‑scheduling (Ley 1008 lists MDMA/MDA among controlled psychotropics); there is no authorized therapeutic program or public reimbursement for MDMA‑assisted therapy in Bolivia, and access is limited to formal, approved clinical research (if any). # Currently there is no recognized national framework for MDMA in psychiatry.

Esketamine (branded forms such as Spravato) is not part of Bolivia's established psychiatric pharmacopeia and there is no publicly available record of a national marketing authorization or reimbursement program for esketamine in Bolivia; esketamine is therefore not reimbursed and is not an approved psychiatric treatment in the Bolivian health system. (I was unable to find a registration entry for Spravato in Bolivian public registries; globally, esketamine approvals and REMS‑style programs are managed by national drug regulators where authorized.) # #

Ketamine is an approved and widely used anesthetic/analgesic in Bolivian clinical practice and appears in local pharmaceutical formularies and product listings for injectable ketamine preparations distributed in Bolivia; its registered indications are surgical anesthesia and analgesia in medical contexts, and it is available within public and private hospitals. # # Regulatory and reimbursement context: ketamine is dispensed/used as a standard anesthetic under the clinical oversight of hospitals and is procured through usual hospital supply channels; however, there is no national, structured reimbursement or clinical‑guideline program in Bolivia approving ketamine for psychiatric indications (e.g., treatment‑resistant depression) as a covered, standardized service. Off‑label psychiatric use—when it occurs in private specialty clinics or research settings—would be handled on a case‑by‑case basis (private billing or clinical trial funding), not as a reimbursed, nationally‑approved mental‑health benefit. Practical note: ketamine is therefore accessible for legitimate medical indications (anesthesia, analgesia) within the health system, but its psychedelic/psychiatric applications lack formal regulatory approval, standard protocols, or public reimbursement.

DMT is explicitly listed among controlled psychotropic substances under Bolivia's Ley 1008 (List I psychotropics) and is treated as a prohibited compound outside authorized activities; there is no authorized medical/therapeutic reimbursement pathway for pure DMT administration. # Separately, the traditional use of DMT‑containing plant mixtures in Amazonian indigenous ritual contexts (ayahuasca) persists in practice, producing a gap between statutory control of the molecule and customary ceremonial uses (see Ayahuasca entry).

Currently classified as a strictly controlled substance in practice (Bolivia's Ley 1008 implements UN psychotropic substance scheduling principles and controls a broad set of tryptamines and analogues) with no authorized medical use outside approved clinical research; there is no national therapeutic or reimbursement program for 5‑MeO‑DMT. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Ibogaine is not part of Bolivia's sanctioned therapeutic pharmacopeia and there is no reimbursement pathway.) #

Although the active constituent DMT is controlled under Ley 1008, ayahuasca (traditional plant brews containing DMT and MAO inhibitors) is widely practiced in Amazonian and indigenous ceremonial and healing contexts in Bolivia and is socially tolerated; national law does not provide a formal, clear regulatory authorization for ayahuasca ceremonies, but customary indigenous use is commonly observed and often treated differently in practice than commercial trafficking of controlled substances. This creates a legal tension — the molecule is scheduled but traditional ritual use is culturally accepted and frequently tolerated in the Bolivian Amazon. # #

Mescaline is listed among Schedule I substances in Bolivia's Ley 1008 and is treated as a prohibited psychotropic compound; there is no authorized medical use or national reimbursement program for mescaline outside approved clinical research or narrow, legally‑recognized indigenous sacramental exemptions where applicable. #

Currently classified as a strictly controlled substance family by Bolivia's drug‑control law framework (Ley 1008 adopts the UN conventions' approach to phenethylamine/amphetamine‑type psychotropics and analogues), with no authorized medical use or reimbursement pathway outside approved clinical research. Unauthorized possession/trafficking is subject to standard penal measures under Bolivian law. #